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Introduction
Hip fracture surgery accounts for a major load of any
orthopaedic surgery. Most of the patients are elderly with
multiple comorbids and the estimated one-year mortality
is about 25%.1 Major muscles insert are involved around
the proximal femur and hence these surgeries are
associated with significant intraoperative bleeding,
leading to postoperative anaemia. This in turnmay lead to
reduced functional recovery, resulting in decreased long-
termmortality.2 About one half of all patients undergoing
hip fracture surgery require at least 1100ml of red blood
cell (RBC) transfusion.3
Blood transfusion itself is not free from adverse events. It
can be a source of transmission of various blood-borne
infections and can also cause severe immunological
reactions.4 With recent advances, various methods have
been designed to prevent intraoperative blood loss, like
permissive hypotension, topical freezing saline,
thromboplastic agent and intraoperative administration
of anti-fibrinolytic agent like tranexamic aid (TXA).5 All
these modalities are effective in reducing intraoperative
blood loss, but their role is still unclear.
TXA is an inexpensive pharmacological agent and is a
derivative of amino acid lysine. It occupies lysine sites on
the plasminogenmolecules and therefore causes reduced
formation of activated plasmin which is responsible for
the dissolution of clot. This in turn results in stabilisation
of clot and decreased blood loss. Use of TXA has been
extensively studied in cardiac, spine, maxillofacial and
other surgeries and has been proved to be an important
factor in decreasing operative blood loss and, hence, the
need for postoperative blood transfusion.6-8
With limited literature for TA use in hip fracture surgery,
the current study was planned to compare the frequency
of blood transfusion after surgery for fixation of inter-
trochanteric fractures in patients given TXA versus
placebo.
Patients and Methods
The prospective double blind, randomised control trial
was performed during at the Aga Khan University hospital
from May 1 to October 31, 2014, and comprised patients
between the ages 50 and 90 years diagnosed with Inter-
trochanteric fracture on X-ray imaging. Patients having
multiple fractures on X-ray were excluded and so were
those with rheumatoid arthritis, ischemic heart disease,
pregnant or lactating women, those with known
coagulation disturbances, use of warfarin or other
anticoagulants and allergy to TXA. Written informed
consent was obtained from all participants and the study
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Objective: To compare the frequency of blood transfusion after surgery for fixation of inter-trochanteric fractures in
patients given tranexamic acid versus placebo.
Methods: The randomised control trial was conducted at the Aga khan university hospital from May 1 to October
31, 2014, and comprised patients diagnosed with Inter-trochanteric fracture based on X-ray imaging. The patients
were randomised into two equal groups based on a computer-generated random number table. The Intervention
group received two doses of 10mg/kg body weight of tranexamic acid just before surgery and three hours later
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Numbers of blood transfusions required postoperatively were noted based on the postoperative haemoglobin
readings.
Results: There were 100 patients who were divided into groups of 50(50%) each. Mean post-op haemoglobin for
the intervention groupwas 10.2±2.4 g/dl and for the control group it was 8.9±2.4 g/dl (p=0.007). Nine (18%) patients
in intervention group required blood transfusion compared to 21(42%) in control group (p=0.009).
Conclusion: Administering tranexamic acid was a useful and safe option for reducing requirement of blood
transfusion postoperatively after inter-trochanteric hip fractures.
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was approved by the institutional ethics review
committee.
The patients were randomly allocated into two equal
groups using a computer-generated random number
table which was prepared using the help of a senior
statistician. Patients in intervention TXA group received
two doses of 15mg/kg body weight of TXA, while those in
the control group received two doses of 15mg/kg body
weight of placebowhichwas normal saline, intravenously.
In both groups the first dose was administered just before
surgery and the second was given 3 hours later. An
orthopaedic Resident not part of the primary surgical
teamwas responsible for administration of the placebo or
TXA while keeping the investigator and primary surgery
team blinded. Neither the patient nor the investigator
knew of the group allocation.
Haemoglobin (Hb) was measured preoperatively (pre-op
Hb) and at 24 hours postoperatively (post-op Hb). All
patients were given routine prophylaxis for DVT with
injection Enoxaparin 40mg subcutaneously once a day. To
minimise bias, all patients were operated upon by a senior
orthopaedic surgeon with minimum 5 years of
experience. Patients who were required to receive blood
transfusion were noted. Blood was transfused if the post-
op Hb was <7g/dl.
Data was analysed using SPSS 20. Continuous variables
were expressed as mean ± standard deviation (SD) and
categorical variables were expressed as frequencies and
percentages. For comparison of means, Independent
sample t-test was used and Chi-square test was used for
comparison of categorical variables. P<0.05 was
considered significant.
Results
There were 100 patients who were divided into groups of
50(50%) each. There were no significant differences
between the groups in terms of age, gender, site, pre-op
Hb and duration of surgery (p>0.05 each) (Table-1).
The mean post-op Hb 24 hours after surgery was 10.2±2.4
g/dl for the intervention group, while it was 8.9±2.4 g/dl
for the control group (p=0.007).
There was a significant difference in the requirement of
blood transfusion between the groups (p=0.009) (Table-
2). The relative risk (RR) for transfusion was 0.51 when TXA
was administered compared to when placebo was
administered.
Discussion
The role of TXA in reducing surgery-related blood loss,
and, hence, the need for blood transfusion, has been
researched a lot in different surgical fields, including
orthopaedics. A randomised control trial (RCT) performed
in 2001 showed that there was significantly less
intraoperative blood loss and need for blood transfusion
in patients receiving TXA for scoliosis surgery.7 A meta-
analysis of 129 RCTs, carried out in 2012 also concluded
that the probability of receiving transfusion after surgery
was reduced by one-third after administering TXA.9
Benoni G et al. conducted a study to assess the role of TXA
in total knee replacement (TKR). Two doses of 10mg/kg
body weight of TXA were administered; one before
release of tourniquet and the second three hours later.
Giving TXA significantly reduced the amount of blood loss
and the need for blood transfusion.10 Similarly, other trials
and meta-analyses have also shown similar results after
total hip and knee replacement procedures.11-13
Despite havingmany studies to evaluate the role of TXA in
surgeries, limited literature is available on its role in hip
fracture surgeries. In an RCT, TXA was administered as an
initial bolus dose of 500mg before surgery followed by
continuous infusion at 1mg/kg/h for the duration of
surgery. Results showed that the differences in mean
reduction in Hb and mean volume of blood loss
postoperatively between TXA and placebo groups were
significant. In addition, only 7 out of 45 patients in TXA
group required blood transfusion compared to 18 out of
45 in placebo group and the difference was again
significant.5 On the contrary, another RCT in 2010
concluded that there was no significant difference in
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Table-1: Baseline Characteristics.
Characteristics Intervention group Control group P-value
(n=50) (n=50)
Age (years) 69.0±10.0 70±9.4 0.6
Gender
Male 21 24 0.5
Female 29 26
Site
Right 27 31 0.4
Left 23 19
Pre-op Haemoglobin (g/dl) 11.5±1.8 11.3±1.7 0.7
Duration of surgery (mins) 112.9±46.7 112.3±47.7 0.9
Table-2: Comparison of blood transfusion between intervention and control groups.
Blood Transfusion P-value Relative Risk
Yes (n=50) No (n=50)
TXA group 9 (18%) 41 (82%) 0.009 0.51 (0.29-0.92)
Control group 21 (42%) 29 (58%)
TXA: Tranexamic acid.
blood transfusion rates between TXA and placebo groups
after surgery for hip fracture.3 Therefore, although
effectiveness of TXA in reducing post-surgical blood loss
and transfusion requirements have been shown by
multiple studies, but its effectiveness, specifically in hip
fracture surgeries, is yet to be established.
Blood loss in hip fracture surgeries is different from those
in elective procedures of hip and knee joint because in hip
fractures, the fibrinolytic system gets activated at the time
of trauma and continues to increase during surgery.5 As a
result, these surgeries are associated with increased blood
loss and increased requirement of blood transfusions.
Therefore, it is important to assess the role of TXA in hip
fracture surgeries separately. The current study showed
that in hip fracture surgery, the need for blood transfusion
was significantly reduced in patients receiving TA, as 18%
patients in intervention group versus 42% in control
group required blood transfusion. This is comparable to a
trial in which 15.5% patients in TXA group and 40% in
control group required transfusion after hip fracture
surgery.5 These results substantiate the findings of
previously mentioned studies regarding the importance
of TXA in surgical procedures.
The pre-op and post-op Hb was also comparable to
another study conducted in Iran in 2007 in which a bolus
dose of 15mg/kg body weight of TXA was administered at
the time of induction of anaesthesia. The pre-op Hb for
TXA and control group was 11.1±2.2 and 11.4±1.3 g/dl
respectively and post-op Hb was 10.1±1.4 and 8.9±2.1
g/dl respectively. This study also showed that TXA is
associated with reduced post-surgical blood
transfusions.14
A few surgeons also believe that TXA increases the risk of
thromboembolic events, including DVT and pulmonary
embolism (PE).15 But during our study, no such
complication was noted in the intervention group. This is
also supported by a meta-analysis conducted in 2003
which concluded that TXA is not associated with an
increased risk of thromboembolic accidents.16
Administering TXA is also more cost-effective compared
to transfusing blood, and therefore increasing its use in
reducing the requirement for transfusion will result in
decreased economic burden on health system, which is a
bonus, especially in developing countries like
Pakistan.17,18
Although this study successfully proves the effectiveness
of TXA, but some of the confounding factors which could
have affected the results include bodymass index (BMI) of
the patients, American Society of Anaesthesiologists
(ASA) status and use of any anti-coagulants prior to the
surgery by the patients. The study also takes into account
only the post-op Hb measured 24 hours after surgery. To
further substantiate the results, volume of blood loss
intraoperatively and postoperatively can also be
measured. Hb levels can also bemeasured daily for a week
after surgery to evaluate the long-term effect of TXA.
Further studies can also be carried out to test the
effectiveness of TA in different types of orthopaedic
fractures.
Conclusion
Administering TXA was a safe and useful option for
reducing the need for blood transfusion after surgery for
inter-trochanteric hip fractures.
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